Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress  by Pupim, Lara B. et al.
Kidney International, Vol. 65 (2004), pp. 2371–2379
Influence of initiation of maintenance hemodialysis on
biomarkers of inflammation and oxidative stress
LARA B. PUPIM, JONATHAN HIMMELFARB, ELLEN MCMONAGLE, YU SHYR, and T. ALP IKIZLER
Department of Medicine, Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee; Department of
Medicine, Division of Nephrology, Maine Medical Center, Portland, Maine; and Department of Biostatistics, Vanderbilt University
Medical Center, Nashville, Tennessee
Influence of initiation of maintenance hemodialysis on
biomarkers of inflammation and oxidative stress.
Background. Chronic inflammation and oxidative stress are
highly prevalent in patients with chronic kidney disease and
end-stage renal disease (ESRD). These conditions contribute
to high mortality rates associated with cardiovascular disease,
the leading cause of death in this patient population. To our
knowledge, no prospective studies have examined how initia-
tion of maintenance hemodialysis (MHD) affects biomarkers
of inflammation and oxidative stress status.
Methods. This was a prospective cohort study evaluat-
ing time-dependent changes in C-reactive protein (CRP),
interleukin-6 (IL-6), interleukin-10 (IL-10), and protein car-
bonyl content before and after initiation of MHD over a
12-month period. Fifty incident hemodialysis patients [57.6 ±
17.2 years, 60% male, 38% Caucasians, 32% insulin-dependent
diabetes mellitus (IDDM) were studied, with 50 healthy sub-
jects for comparison. The study variables were assessed be-
fore the initial outpatient hemodialysis treatment, and every
3 months thereafter for 12 months.
Results. At baseline, CRP, IL-6, and carbonyl content lev-
els were significantly higher in MHD patients compared with
healthy subjects (P < 0.001 for each). After initiation of MHD,
there were no significant changes in any of the study variables.
Patients who initiated MHD with the highest levels of all the
study variables had a significant decrease over the next year,
but the variables were still higher than normal at the end of the
12-month study period.
Conclusion. Our data show that initiation of MHD does not
have significant influence on plasma concentrations of CRP, IL-
6, and IL-10, as well as plasma protein carbonyl content. These
findings suggest that MHD is ineffective in controlling inflam-
mation and oxidative stress in uremia.
Patients with advanced chronic kidney disease develop
a variety of signs and symptoms related to uremic toxicity,
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including gastrointestinal [1], neurologic [2], and cardiac
symptomatology [3]. Uremia is also characterized by a
variety of metabolic perturbations, including metabolic
acidosis [4], hyperphosphatemia [5], azotemia, and disor-
ders of volume homeostasis [6]. Maintenance hemodialy-
sis (MHD) therapy is initiated to lessen uremic symptoms,
improve nutritional status, improve the metabolic milieu,
and to sustain and improve the overall quality of life. Un-
fortunately, however, mortality and morbidity rates of
patients receiving maintenance dialysis therapy remain
unacceptably high despite demonstrable improvements
in metabolic parameters, volume homeostasis, and nutri-
tional status [7, 8] that occur after dialysis is initiated [9].
The HEMO Study, the largest and most comprehensive
randomized trial ever undertaken in the MHD popula-
tion, was designed to test the hypothesis that either in-
creasing the delivered dose of dialysis, or increasing dial-
ysis membrane flux would improve all-cause mortality in
a prevalent MHD population [10]. The primary results of
this comprehensive trial have recently been reported and
support the null hypothesis for both dose of dialysis and
membrane flux. In light of the HEMO Study primary re-
sults, a systematic re-examination of the relative benefits
or lack of benefits of the dialysis procedure on determi-
nants of mortality in uremic patients is indicated [11]. To
critically evaluate how initiation of dialysis affects ure-
mic factors that contribute to mortality, prospective co-
hort studies of the incident dialysis population should be
particularly valuable.
Cardiovascular disease remains the leading cause of
morbidity and mortality in the maintenance dialysis pop-
ulation [12]. Data increasingly suggest that a cytokine-
driven acute-phase inflammatory response and an
increase in oxidative stress status are highly prevalent in
the maintenance dialysis population, and closely associ-
ated with the pathogenesis of cardiovascular disease [13,
14, 15]. To our knowledge, no prospective studies have
examined how initiation of MHD affects biomarkers of
inflammation and oxidative stress status. We therefore
performed a prospective cohort in a group of incident
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Table 1. Demographic characteristics of the patients studied
MHD patients Healthy subjects
Gender M/F 30 (60%)/20 (40%) 18 (36%)/32 (64%)
Race %
Caucasian 40 94
African American 60 06
Age years (mean ± SD) 57.6 ± 17.2 49.7 ± 16.3
(range 24–90) (range 24–85)
Cause of ESRD %
Diabetes 30 N/A
Hypertension 24 N/A
Glomerulonephritis 24 N/A
Polycystic kidney disease 8 N/A
Other 12 N/A
Unknown 4 N/A
Abbreviations are: MHD, maintenance hemodialysis; M, male; F, female;
ESRD, end-stage renal disease.
hemodialysis patients evaluating time-dependent
changes in biomarkers of inflammation (IL-6, IL-10,
and CRP levels) and oxidative stress (plasma protein
carbonyl content).
METHODS
Patient characteristics
The study was conducted at the Vanderbilt University
Outpatient Dialysis Unit. All newly initiated MHD pa-
tients were asked to participate in the study. The study
period was from December 1997 through November
2000, and included all consenting patients surveyed from
December 1997 to November 1999. There were no exclu-
sion criteria (except age <18 years), and all incident pa-
tients were referred to enrollment in the study. Between
December 1997 and November 1999, a total of 73 new
patients were initiated on MHD at the Dialysis Unit. Of
those 73 patients, 50 patients (68%) consented to partic-
ipate in the study and were followed for 12 months. The
only cause of nonenrollment was refusal by the patient. A
group of 50 healthy subjects served as the control group
only for the initial measurement of the study. In addi-
tion, CRP, IL-6, and carbonyl content were measured in
29 patients with diabetes and other comorbid conditions,
such as cardiovascular disease and/or hypertension but
no end-stage renal disease (ESRD), for a baseline com-
parison. The Institutional Review Board approved the
study protocol and written consent was obtained from all
study subjects.
Of the 50 study patients, 30 (60%) were male and 20
(40%) were female. Specific demographic characteristics
are shown in Table 1. Forty-one (82%) patients had com-
plete follow-up until the end of the study, 4 patients died
during the study, and 5 patients were lost to follow-up
(4 patients transferred to another facility, and 1 patient
received a liver transplant). The causes of death in the
4 patients were infection (1), cardiovascular (2), and un-
known (1).
Study design
This was a prospective cohort study. There were no in-
terventions specific to the study protocol. Each patient’s
attending nephrologist determined the timing of initia-
tion of MHD and the dialysis prescription was according
to the facility protocol (see below). The study variables
consisted of serial measurements of biomarkers of inflam-
mation and oxidative stress every 3 months for a period
of 12 months after initiation of MHD. In a previous study
with similar patient population we reported the trends
in nutritional markers, as well as certain dialytic charac-
teristics, over 12 months [7]. Table 2 shows serum albu-
min, serum prealbumin, and dialysis dose (Kt/V) values
in the study patients. Baseline blood samples were col-
lected immediately before the first outpatient hemodial-
ysis treatment. Biochemical indices followed during the
study included plasma IL-6 (IL-6), plasma IL-10 (IL-10),
plasma protein carbonyl content, and serum CRP levels.
The most recent measurements of 24-hour urine creati-
nine excretion before the initiation of MHD (range of 1 to
90 days) were used to calculate baseline creatinine clear-
ance and were repeated at the 12-month interval. Twenty-
four–hour creatinine excretion was available in 41
patients (82%). Dialysis adequacy was assessed by kinet-
ically determined Kt/V and urea reduction ratio (URR)
measurements at each study time point.
Blood samples were obtained prehemodialysis in a
nonfasting state at the beginning of the week, after two
consecutive days without treatment, except for the initial
sampling, which occurred on the day the patient initi-
ated MHD therapy. During the study period, none of the
study patients had a known acute inflammatory event at
the time of blood draws (no hospitalization event within
1 week of scheduled sampling time, excluding the patients
who were hospitalized for initiation of hemodialysis at
the baseline measurement and not on antibiotic therapy).
Blood was drawn into Vacutainer tubes containing ethyl-
diaminetetraacetic acid (EDTA) supplemented with
1000 U/mL catalase and centrifuged at 1700g for 15 min-
utes or into serum separator tubes.
Serum CRP levels were measured using high-
sensitivity immunoturbidimetric assay by Roche Mod-
ular System (Indianapolis, IN, USA). Plasma IL-6 and
IL-10 concentrations were determined by enzyme-linked
immunosorbent assay (ELISA) with kits from BioSource
International (Camarillo, CA, USA).
Plasma protein carbonyl content was measured us-
ing the Zentech PC Test (Protein carbonyl Enzyme
Immuno-assay Kit; Zenith Technology, Dunedin, New
Zealand) as described previously. This kit follows the
method outlined by Buss et al [16] as amended by Winter-
bourn and Buss [17], which utilizes derivatization of pro-
tein carbonyl in samples and oxidized protein standards
with dinitrophenylhydrazine, followed by ELISA with an
anti-DNP antibody and standard ELISA techniques for
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Table 2. Serum proteins and dialysis dose at follow-up time points during 12 months of study
Baseline 3 months 6 months 9 months 12 months
N = 50 N = 50 N = 46 N = 41 N = 41
Serum albumin g/dLa 3.36 ± 0.08 3.59 ± 0.07 3.62 ± 0.07 3.72 ± 0.06 3.63 ± 0.06
Serum prealbumin mg/dLa 30.1 ± 1.25 33.1 ± 1.49 34.5 ± 1.70 34.6 ± 1.34 32.6 ± 1.51
Kt/Va 1.37 ± 0.3 1.45 ± 0.3 1.49 ± 0.3 1.66 ± 0.4 1.57 ± 0.3
Values reported are the mean ± SEM of each period for each variable.
aDenotes significant trends over time, P < 0.001, by mixed-model procedure.
labeling and visualizing labeled molecules [16]. Ab-
sorbance is read at 450 nm on an MRX microplate reader
(Dynex Technologies, Chantilly, VA, USA). A standard
curve is plotted, and the carbonyl concentration of sam-
ples is read off the curve, using the MRX Revelation Soft-
ware (Dynex Technologies).
Assay analytical sensitivity was 2.0 pg/mL, 1.0 pg/mL
for IL-6 and IL-10, respectively. Interassay variability was
6% and 3%, and intra-assay variability was 8% and 4%
for IL-6 and IL-10, respectively. Carbonyl content assay
had the following characteristics: 0.021 nmol/mg of ana-
lytical sensitivity and 3.8% of intra-assay variability. The
interassay variability for carbonyl assay was 5.8% for high
values, 7.7% for medium values, and 24.7% for low values.
Analytical sensitivity of CRP was 0.003 mg/dL, with an
interassay variation of 5.9%, 3.0%, and 2.4%, respec-
tively for low, medium, and highest values, and an intra-
assay variation of 1.3%, 0.4%, and 0.3% for low, medium,
and highest values.
All patients underwent formal urea kinetic modeling
at each data collection during the study period. The mini-
mum dialysis dose delivered at the dialysis unit was Kt/V
greater than or equal to 1.4 (single pool). All patients
were dialyzed with high-flux biocompatible membranes
(Fresenius F80; Fresenius USA, Lexington, MA, USA).
The dialysate used was identical for all treatments and
consisted of sodium 139 mEq/L, potassium 2 mEq/L, cal-
cium 2.5 mEq/L, glucose 200 mg/dL, and bicarbonate
39 mEq/L.
Dialyzers were reused with formaldehyde and bleach
for a maximum of 30 times, with an average of 18 reuses.
The process of reuse involved an initial exposure to a
diluted bleach solution (0.375%), rinsing of the bleach,
and sterilizing with formaldehyde diluted to a concen-
tration of 1.5% using the Fresenius DRS-4 machine
(Fresenius USA). Dialyzers were then stored for a min-
imum of 24 hours before the subsequent patient’s blood
contact. Dialysate quality was checked on a quarterly ba-
sis, and the bacteria and endotoxin levels have all been
below highest acceptable limits (less than 50 CFU/mL
and less than 0.99 EU/mL).
Study patients’ calcium, phosphorus, total bicarbon-
ate, and hematocrit levels were included in regular pa-
tient monthly laboratory reports. Every effort was made
to keep laboratory parameters within acceptable ranges
through established protocols. Recombinant human ery-
thropoetin and intravenous iron were prescribed to keep
hematocrit within the range of 33% to 36% and transfer-
rin saturation greater than 20%.
Statistical analysis
Analyses of results focused on estimating the profile
changes of biomarkers of inflammation and oxidative
stress in ESRD upon initiation of MHD and over the
12-month study period. The null hypothesis was that ini-
tiation of MHD would not change levels of biomark-
ers of inflammation and oxidative stress in ESRD
patients. The primary end point was circulating levels of
IL-6. Fifty incident hemodialysis patients accepted and
were included in this study during the enrollment pe-
riod. With a sample size of 50, we estimated to have 93%
power to detect a 10% difference in IL-6 means from
baseline to the end of 1 year (i.e., an average change
of 2.0 pg/mL in the means of IL-6 from baseline to
12-month time-point), assuming a standard deviation of
the differences of 4.0 pg/mL (effect size of 0.5), using a
paired t test approach and a two-sided 0.05 alpha level
[18]. We anticipated having a 20% dropout rate in 1 year.
Indeed, our sample size was 41 at the end of the study
period, which provided 87% of power to detect the dif-
ferences estimated above. Correlations among the study
variables were performed by correlation matrix mixed
procedure [19]. Comparisons of study variables between
healthy control patients and the study population were
done with the Student t test for normally distributed
data and the Mann-Whitney U test for non-normally
distributed data. The trends of study variables over
the 12-month study period were analyzed using the re-
stricted/residual maximum likelihood-based mixed effect
model to adjust the intracorrelation effect for patients
who had multiple measurements [20]. For this analysis,
logarithmic transformation was used to account for the
skewed distribution of IL-6, IL-10, and plasma carbonyl
content. The model was selected based on Akaike’s Infor-
mation Criterion and Schwarz’s Bayesian Criterion [21].
All tests of significance were two-sided, and differences
were considered statistically significant when P value was
less than 0.05. All data are expressed as mean ± SEM un-
less otherwise stated. SAS version 8.2 (Cary, NC, USA)
was used for all analyses.
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Table 3. Biomarkers of inflammation and carbonyl levels at baseline
comparing MHD patients and healthy subjects
MHD patients Healthy subjects P value
IL-6 pg/mL 20.17 ± 4.32 4.02 ± 0.47 <0.001
CRP mg/dL 2.01 ± 0.06 0.28 ± 0.06 <0.001
IL-10 pg/mL 2.91 ± 0.86 1.06 ± 0.16 0.249
Carbonyl 0.154 ± 0.014 0.029 ± 0.004 <0.001
nmol/mg protein
Abbreviations are: IL-6, interleukin-6; IL-10, interleukin-10; CRP, C-reactive
protein. Values reported are the mean ± SEM of each period for all variables.
RESULTS
Biomarkers of inflammation and oxidative stress
are increased at initiation of hemodialysis
We initially compared the study variables in the
hemodialysis study population with 50 healthy sub-
jects. The patients had significantly higher levels of IL-6
(20.17 ± 4.32 pg/mL vs. 4.02 ± 0.47 pg/mL, P < 0.001),
CRP (2.01 ± 0.06 vs. 0.28 ± 0.06 mg/dL, P < 0.001), and
carbonyl content (0.154 ± 0.014 nmol/mg of protein vs.
0.029 ± 0.004 nmol/mg of protein, P < 0.001) at the time
of initiation of MHD therapy (Table 3). IL-10 levels were
numerically lower in the healthy population compared
with the ESRD population, but the difference did not
reach statistical significance (1.06 ± 0.16 pg/mL vs. 2.91 ±
0.86 pg/mL, respectively, P = 0.249). When compared
with diabetics without renal failure (63 ± 14 years old,
70% males), CHD patients had significantly higher lev-
els of carbonyl content (0.154 ± 0.014 nmol/mg of protein
vs. 0.021 ± 0.004 nmol/mg of protein, P < 0.001), IL-6
(20.17 ± 4.32 pg/mL vs. 6.05 ± 1.85 pg/mL, P = 0.015),
and CRP (2.01 ± 0.06 mg/dL vs. 0.76 ± 0.2 mg/dL, P =
0.030) at the time of initiation of MHD therapy.
Biomarkers of inflammation and oxidative stress
are stable during the first year of MHD
Directional changes of plasma IL-6, plasma IL-10,
serum CRP, and plasma carbonyl content were analyzed
over a period of 12 months. There were no significant
changes in any of the study variables over the study pe-
riod. This was consistent for overall trends as well as
comparisons of each time point to baseline. Specifically,
plasma IL-6 levels changed from 20.17 ± 4.32 pg/mL at
baseline to 15.94 ± 4.22 pg/mL at 6 months, and 18.22 ±
5.27 pg/mL at 12 months’ follow-up (P = 0.983 for the
trend) (Fig. 1). Serum CRP levels changed from 2.01 ±
0.06 mg/dL to 1.79 ± 0.07 mg/dL at 6 months, and to 1.25 ±
0.08 mg/dL at 12 months (P = 0.651) (Fig. 2). IL-10 con-
centrations were 2.91 ± 0.86 pg/mL at baseline, 0.94 ±
0.84 pg/mL at 6 months, and 1.00 ± 0.09 pg/mL at
12 months (P = 0.121). Plasma carbonyl content also de-
creased from 0.154 ± 0.014 nmol/kg of protein to 0.122 ±
0.013 nmol/kg of protein in the first 6 months, but dis-
played a subsequent increase to 0.162 ± 0.017 nmol/kg of
protein in 12 months (P = 0.887) (Fig. 3).
Changes in biomarkers of inflammation are dependent
on baseline concentrations
An analysis of trends over time based on initial quar-
tiles for study variables was conducted. The trends were
dependent on the initial baseline values of study vari-
ables. Figure 4 shows this analysis for IL-6. As can be
seen, patients who initiated MHD with highest levels of
IL-6 at baseline (Q4) experienced a significant decrease
in IL-6 concentrations over the study period (58.02 ±
14.06 pg/mL to 19.15 ± 4.33 pg/mL, P = 0.036). On the
contrary, patients who initiated MHD therapy in the two
lowest quartiles of IL-6 (Q1 and Q2) increased their levels
significantly (from 2.59 ± 0.30 pg/mL to 12.77 ± 1.30 pg/
mL for Q1, P < 0.001, and from 6.48 ± 0.38 to 20.77 ±
4.97 pg/mL for Q2, P = 0.029). Patients in the Q3 group
had a trend for increase but it did not reach statistical sig-
nificance (13.57 ± 1.43 pg/mL to 19.19 ± 4.65 pg/mL, P =
0.647). Similar trends were observed for IL-10, CRP, and
carbonyl content. Figures 5 and 6 show these trends for
CRP and carbonyl content, respectively. Most important,
none of the quartiles for any study variable reached nor-
mal values at the end of the 12-month study period. For
example, at the end of 1 year of MHD, levels of IL-6 were
12.77 pg/mL, 20.77 pg/mL, 19.19 pg/mL, and 19.15 pg/mL
for Q1, Q2, Q3, and Q4, respectively. Levels of CRP, IL-
10, and carbonyl content remained similarly elevated at
the end of the study period.
Lack of influence of residual renal function and other
clinical parameters
To elucidate any potential interaction of residual re-
nal function on the observed outcomes, we analyzed
the adjusted association of residual renal function, as-
sessed by 24-hour urine creatinine clearance, with the
study variables, by mixed model procedure. No significant
associations were found between the baseline creatinine
clearance and the future trends of CRP (P = 0.384), IL-6
(P = 0.863), IL-10 (P = 0.721), or carbonyl content (P =
0.391).
We additionally analyzed the trends in biomarkers of
inflammation and oxidative stress according to the type
of vascular access, concurrent illnesses, and the presence
of diabetes. Our results suggested that the presence of
diabetes, when analyzed separately, was associated with
significant increases in carbonyl content over the study
period (P = 0.040), although the trends in nondiabetics
(P = 0.756) and the overall trends were not statistically
significant. Analyses of the other study variables were
not affected by the presence of diabetes. Hypertension,
cardiovascular disease, and type of vascular access did
not influence trends in any of the study variables.
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Fig. 2. Black bars represent changes in serum
C-reactive protein (CRP) concentration at
follow-up time points during 12 months of
study. White bar represents one time-point
measurement in healthy control patients. Bars
and error bars represent mean ± SEM for
each time point.
Correlations among study variables
The associations among the four study variables were
analyzed in a multivariate matrix correlation by mixed-
model procedure. There were significant positive corre-
lations comparing CRP with IL-6 (estimate = 0.546, P =
0.012), and CRP with IL-10 (estimate = 1.893, P < 0.001).
CRP correlated substantially with carbonyl content,
but it did not reach statistical significance (estimate =
1.330, P = 0.599). IL-6 was negatively correlated with
IL-10 but this correlation was not statistically significant
(estimate = −0.067, P = 0.678).
DISCUSSION
The current study was designed to determine the in-
fluence, if any, of initiation of conventional MHD on cir-
culating levels of biomarkers of inflammation (cytokines
and CRP), as well as a marker of oxidative stress (plasma
protein carbonyl content). Our results showed that the
levels of CRP, IL6, and carbonyl content were signifi-
cantly higher in patients than healthy control patients at
baseline. IL-10 was numerically higher in patients than
control patients, but the difference did not reach statis-
tical significance. In addition, there were no significant
changes in any study variable over a 12-month period af-
ter initiation of MHD. After subdividing patients accord-
ing to their baseline level of each study variable, highest
values decreased significantly for all variables, and low-
est values increased significantly for IL-6, IL-10, and car-
bonyl content. These findings are in accordance with the
statistical occurrence known as regression to the mean,
suggesting that the study intervention (i.e., hemodialysis)
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has no significant effect on inflammation or oxidative
stress in MHD patients. The [lack of] changes in biomark-
ers of inflammation and oxidative stress over time were
independent of clinical covariates, such as presence or
absence of diabetes with cardiovascular disease and/or
hypertension, as well as the type of vascular access used.
Acute-phase inflammation is a common feature of
ESRD and it is estimated that 30% to 50% of ESRD
patients have serologic evidence of an activated inflam-
matory response [13]. The plasma levels of the prototyp-
ical acute-phase protein CRP have been demonstrated
in numerous studies to be a powerful predictor of subse-
quent cardiovascular events and all-cause mortality in the
dialysis population [22, 23]. Plasma IL-6 levels are also in-
creasingly being recognized as an independent predictor
of cardiovascular events, progression of atherosclerosis,
and all-cause mortality in the dialysis population [24–28].
In this study, we also measured plasma levels of
the anti-inflammatory cytokine IL-10. IL-10 is known
to counter-regulate the cascade of proinflammatory cy-
tokines, including IL-6, as part of the acute-phase reac-
tion. The importance of IL-10 as an anti-inflammatory
cytokine is emphasized by a recent study in which a low-
producing IL-10 gene polymorphism was associated with
a higher cardiovascular morbidity and mortality in a co-
hort of MHD patients [29]. Early data suggested that
plasma levels of IL-6 and IL-10 were inversely related
in the hemodialysis population [30]. Other studies have
demonstrated overproduction of IL-10 in the hemodial-
ysis population [31]. A recent study using a sensitive
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technique measuring monokine production at the single
cell level demonstrated that monocytes from hemodialy-
sis patients tend to overproduce both IL-6 and IL-10 si-
multaneously, while healthy subjects’ monocytes produce
IL-6 and IL-10 in separate monocyte subpopulations [32].
In the present study, a trend toward higher plasma lev-
els of IL-10 was detected in dialysis patients compared
with healthy subjects with a significant relationship to
CRP levels. Similar to IL-6, plasma IL-10 levels did not
change significantly over the course of time after initia-
tion of MHD therapy.
The underlying etiology of the accentuated inflam-
matory response in uremia remains poorly understood.
While multiple dialysis-related factors can contribute to
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maintenance of a chronic inflammatory response, recent
data demonstrating that plasma IL-6 and CRP levels are
already elevated in earlier stages of chronic kidney dis-
ease suggest a more proximate relationship to loss of kid-
ney function [33]. Indeed, our results clearly show that
plasma levels of cytokines and carbonyl content were
significantly elevated at the time of initiation of main-
tenance hemodialysis. Loss of renal function may be di-
rectly associated with reduced clearance of cytokines,
complement peptides, oxidants, and other proinflamma-
tory solutes. Additionally, the hemodialysis procedure
itself may contribute to a proinflammatory milieu by in-
creasing the synthesis of fibrinogen, IL-6, and other proin-
flammatory peptides, likely by bioincompatibility from
membrane and dialysate exposure during the extracor-
poreal procedure [34]. However, in this study we did not
observe a significant increase in inflammatory markers
during the initial 12 months of MHD. This is in contrast
to a report by Haubitz et al in which significant increases
in CRP levels were reported after initiation of MHD in 8
patients. While the exact reasons for this discrepancy are
not clear, it should be noted that the sample size in the
former study was relatively small and the patients were
dialyzed with a bioincompatible membrane, which might
have initiated an inflammatory response, per se [35].
An increase in oxidative stress is increasingly rec-
ognized as an important metabolic accompaniment to
ESRD [36]. Reactive oxygen species are known to ac-
tivate phagocytic cells and, by way of NF-jB, up-regulate
the release of IL-6 and increase production of CRP [37].
Our group has recently described a linkage between in-
creased oxidative stress and acute-phase inflammation
in severely hypoalbuminemic MHD patients [38]. In the
present study, we have measured plasma protein carbonyl
content as a biomarker of oxidative stress status [39–41].
The importance of increased carbonyl is evidenced by
their important role in the pathogenesis of atherosclero-
sis [42]. The present study confirms high levels of plasma
protein carbonyl content in patients with advanced kid-
ney disease, and demonstrates no significant effect of ini-
tiating MHD therapy on plasma carbonyl content over
time. Similar to the data on biomarkers of inflammation,
these data suggest that initiation of MHD therapy is not
adequate to control oxidative stress in uremia.
A corollary interpretation of the data in this study
is that the hemodialysis procedure itself is not the
predominant cause of the increased oxidative stress and
inflammation observed in the ESRD population. Thus,
hemodialysis may not accelerate atherogenesis, so much
as simply not abate its development. This suggestion is
supported by a growing body of evidence demonstrating
that many proatherogenic metabolic alterations in ure-
mia are already present before the initiation of dialysis
therapy. Furthermore, previous work by our group and by
other investigators has demonstrated that the net effect
of a single hemodialysis treatment is to improve overall
redox balance [39]. Even when bioincompatible mem-
branes, which vigorously activate the alternative pathway
of complement are used, it is extraordinarily difficult to
detect an increase in oxidative stress over the course of
the dialysis procedure. Thus, an important potential im-
plication of this study and other similar studies is that
improvements in the proatherogenic metabolic milieu in
uremia will require the removal or biologic inactivation
of solutes not readily cleared by the diffusive process in
hemodialysis therapy. Either alternative types of renal
replacement therapy (such as hemodiafiltration or the
renal tubular assist device) or pharmacologic therapies
(such as antioxidants or anti-inflammatory agents) may
be required to control the uremia-associated oxidative
stress and inflammation.
The present study in incident MHD patients should
not be viewed as an attempt to quantitatively measure
the potentially competing effects of hemodialysis and
uremia on inflammation and oxidative stress biomark-
ers. Instead, it should be viewed rather as an analysis
of changes observed in these parameters after definitive
initiation of conventional MHD therapy in patients with
advanced ESRD. While a randomized controlled trial is
always preferable, such design is not applicable for the
hypothesis tested in this study. The current data must
also be evaluated in the context of recent publications
suggesting that initiation of MHD is associated with im-
provements in several nutritionally and metabolically rel-
evant markers to some extent [7, 8]. In a similar group of
patients, we observed an increase in serum albumin and
serum prealbumin in the setting of increased solute clear-
ance at adequate levels [7]. The results from this study,
on the other hand, show that such an effect is not ob-
served for inflammation or oxidative stress markers, im-
portant contributors to the high cardiovascular morbidity
and mortality observed in ESRD patients. Together with
the context of the recent HEMO Study results, we can
postulate that conventional dialysis is “inadequate” as
an anti-inflammatory and antioxidant therapy.
CONCLUSION
We have shown that ESRD patients have substantially
increased inflammatory and oxidative stress burden at the
initiation of MHD treatment with currently prescribed
treatment parameters. Our results suggest that conven-
tional MHD is not effectively treating the highly preva-
lent inflammation and oxidative stress in ESRD patients.
The lack of effective therapy for these metabolic pertur-
bations may contribute to an ongoing high cardiovascular
morbidity and mortality. Further research is needed to
elucidate the mechanistic pathways of inflammation and
oxidative stress, both before and after MHD is initiated.
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